Table 2.
Summary of Adverse Ocular Events Following COVID–19 Vaccination Reported In Population-Based Pharmacovigilance Surveillance Systems18-22
| Adverse Ocular Event | Vaccine | European Union |
United States |
United Kingdom1 |
Canada |
Australia1 |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Prevalence (Cases Per Million Doses) | Cases | Prevalence (Cases Per Million Doses) | Cases | Prevalence (Cases Per Million Doses) | Cases | Prevalence (Cases Per Million Doses) | Cases | Prevalence (Cases Per Million Doses) | ||
| Ocular Inflammatory Disease | |||||||||||
| Uveitis | Pfizer/BioNTech | 121 | 0.3 | 39 | 0.2 | 37 | – | 1 | 0.02 | 5 | – |
| Moderna | 43 | 0.8 | 40 | 0.3 | 3 | – | 0 | 0 | – | – | |
| AstraZeneca | 53 | 0.8 | – | – | 42 | – | 0 | 0 | 7 | – | |
| Janssen | 3 | 0.2 | 3 | 0.2 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 220 | 0.4 | 82 | 0.2 | 82 | 0.9 | 1 | 0.02 | 12 | 0.6 | |
| Episcleritis | Pfizer/BioNTech | 25 | 0.07 | 19 | 0.09 | 7 | – | 0 | 0 | 0 | – |
| Moderna | 4 | 0.08 | 8 | 0.06 | 4 | – | 0 | 0 | – | – | |
| AstraZeneca | 6 | 0.09 | – | – | 18 | – | 0 | 0 | 2 | – | |
| Janssen | 1 | 0.07 | 0 | 0.00 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 36 | 0.07 | 27 | 0.07 | 29 | 0.3 | 0 | 0 | 2 | 0.1 | |
| Scleritis | Pfizer/BioNTech | 25 | 0.07 | 11 | 0.05 | 3 | – | 0 | 0 | 1 | – |
| Moderna | 11 | 0.2 | 8 | 0.06 | 0 | – | 0 | 0 | – | – | |
| AstraZeneca | 16 | 0.2 | – | – | 13 | – | 0 | 0 | 0 | – | |
| Janssen | 1 | 0.07 | 1 | 0.07 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 53 | 0.1 | 20 | 0.05 | 16 | 0.2 | 0 | 0 | 1 | 0.05 | |
| Herpetic Eye Disease | |||||||||||
| Ophthalmic herpes zoster | Pfizer/BioNTech | 55 | 0.1 | 0 | 0 | 3 | – | 0 | 0 | 2 | – |
| Moderna | 23 | 0.4 | 0 | 0 | 0 | – | 0 | 0 | – | – | |
| AstraZeneca | 37 | 0.5 | – | – | 10 | – | 0 | 0 | 4 | – | |
| Janssen | 2 | 0.1 | 0 | 0 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 117 | 0.2 | 0 | 0 | 13 | 0.1 | 0 | 0 | 6 | 0.3 | |
| Ophthalmic herpes simplex | Pfizer/BioNTech | 0 | 0 | 0 | 0 | 0 | – | 0 | 0 | 0 | – |
| Moderna | 0 | 0 | 0 | 0 | 1 | – | 0 | 0 | – | – | |
| AstraZeneca | 0 | 0 | – | – | 1 | – | 0 | 0 | 1 | – | |
| Janssen | 0 | 0 | 0 | 0 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 0 | 0 | 0 | 0 | 2 | 0.02 | 0 | 0 | 1 | 0.05 | |
| Anterior Segment Conditions | |||||||||||
| Corneal graft rejection | Pfizer/BioNTech | 10 | 0.03 | 1 | 0.005 | 5 | – | 0 | 0 | 0 | – |
| Moderna | 2 | 0.04 | 0 | 0 | 0 | – | 0 | 0 | – | – | |
| AstraZeneca | 3 | 0.04 | – | – | 3 | – | 0 | 0 | 0 | – | |
| Janssen | 0 | 0 | 0 | 0 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 1 | – | – | – | – | – | |
| Total | 15 | 0.03 | 1 | 0.003 | 9 | 0.1 | 0 | 0 | 0 | 0 | |
| Retinal Conditions | |||||||||||
| Macular edema | Pfizer/BioNTech | 24 | 0.06 | 3 | 0.01 | 3 | – | 0 | 0 | 0 | – |
| Moderna | 10 | 0.2 | 6 | 0.04 | 1 | – | 1 | 0.06 | – | – | |
| AstraZeneca | 20 | 0.3 | – | – | 7 | – | 0 | 0 | 0 | – | |
| Janssen | 3 | 0.2 | 1 | 0.07 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 57 | 0.1 | 10 | 0.03 | 11 | 0.1 | 1 | 0.02 | 0 | 0 | |
| Macular degeneration | Pfizer/BioNTech | 17 | 0.05 | 11 | 0.05 | 3 | – | 0 | 0 | 0 | – |
| Moderna | 5 | 0.1 | 5 | 0.03 | 0 | – | 0 | 0 | – | – | |
| AstraZeneca | 10 | 0.1 | 0 | – | 9 | – | 0 | 0 | 1 | – | |
| Janssen | 1 | 0.07 | 1 | 0.07 | – | – | – | – | – | ||
| Unspecified | – | – | – | – | 1 | – | – | – | – | – | |
| Total | 33 | 0.06 | 17 | 0.05 | 13 | 0.1 | 0 | 0 | 1 | 0.05 | |
| Maculopathy | Pfizer/BioNTech | 9 | 0.02 | 3 | 0.01 | 1 | – | 0 | 0 | 0 | – |
| Moderna | 3 | 0.06 | 0 | 0 | 0 | – | 0 | 0 | – | – | |
| AstraZeneca | 7 | 0.1 | – | – | 2 | – | 0 | 0 | 0 | – | |
| Janssen | 0 | 0 | 0 | 0 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 19 | 0.04 | 3 | 0.008 | 3 | 0.03 | 0 | 0 | 0 | 0 | |
| Chorioretinopathy | Pfizer/BioNTech | 11 | 0.03 | 3 | 0.01 | 2 | – | 0 | 0 | 1 | – |
| Moderna | 5 | 0.1 | 2 | 0.01 | 1 | – | 0 | 0 | – | – | |
| AstraZeneca | 8 | 0.1 | – | – | 2 | – | 0 | 0 | 1 | – | |
| Janssen | 0 | 0 | 1 | 0.07 | – | – | – | – | – | ||
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 24 | 0.05 | 6 | 0.02 | 5 | 0.05 | 0 | 0 | 2 | 0.1 | |
| Acute zonal occult outer retinopathy | Pfizer/BioNTech | 0 | 0 | 0 | 0 | 0 | – | 0 | 0 | 0 | – |
| Moderna | 0 | 0 | 0 | 0 | 1 | – | 0 | 0 | – | – | |
| AstraZeneca | 0 | 0 | – | – | 1 | – | 0 | 0 | 0 | – | |
| Janssen | 0 | 0 | 0 | 0 | – | – | – | – | – | ||
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 0 | 0 | 0 | 0 | 2 | 0.02 | 0 | 0 | 0 | 0 | |
| Diabetic retinopathy | Pfizer/BioNTech | 1 | 0.003 | 0 | 0 | 0 | – | 0 | 0 | 0 | – |
| Moderna | 1 | 0.02 | 1 | 0.007 | 0 | – | 0 | 0 | – | – | |
| AstraZeneca | 1 | 0.01 | – | – | 2 | – | 0 | 0 | 0 | – | |
| Janssen | 0 | 0 | 0 | 0 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 3 | 0.006 | 1 | 0.003 | 2 | 0.02 | 0 | 0 | 0 | 0 | |
| Optic Neuropathy | |||||||||||
| Optic neuritis | Pfizer/BioNTech | 136 | 0.4 | 44 | 0.2 | 24 | – | 0 | 0 | 4 | – |
| Moderna | 47 | 0.9 | 31 | 0.2 | 3 | – | 0 | 0 | – | – | |
| AstraZeneca | 96 | 1 | – | – | 51 | – | 0 | 0 | 7 | – | |
| Janssen | 7 | 0.5 | 7 | 0.5 | – | – | – | – | – | ||
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 286 | 0.6 | 82 | 0.2 | 78 | 0.9 | 0 | 0 | 11 | 0.6 | |
| Ischemic optic neuropathy | Pfizer/BioNTech | 51 | 0.1 | 10 | 0.05 | 2 | – | 0 | 0 | 0 | – |
| Moderna | 30 | 0.6 | 15 | 0.1 | 0 | – | 0 | 0 | – | – | |
| AstraZeneca | 25 | 0.4 | – | – | 8 | – | 0 | 0 | 2 | – | |
| Janssen | 3 | 0.2 | 7 | 0.5 | – | – | – | – | – | – | |
| Unspecified | – | – | – | – | 0 | – | – | – | – | – | |
| Total | 109 | 0.2 | 32 | 0.09 | 10 | 0.1 | 0 | 0 | 2 | 0.1 | |
| Glaucoma | Pfizer/BioNTech2 | 34 | 0.09 | 12 | 0.06 | 5 | – | 0 | 0 | 0 | – |
| Moderna | 10 | 0.2 | 9 | 0.06 | 0 | – | 0 | 0 | – | – | |
| AstraZeneca | 21 | 0.3 | – | – | 12 | – | 0 | 0 | 0 | – | |
| Janssen | 1 | 0.07 | 0 | 0 | – | – | – | – | – | – | |
| Unspecified | – | – | – | 0 | 0 | – | – | – | – | – | |
| Total | 66 | 0.1 | 21 | 0.06 | 17 | 0.2 | 0 | 0 | 0 | 0 | |
1
Data for total doses administered by vaccine type were unavailable from the United Kingdom Australia.